B&L Will Shift Optivar Reps To Anticipated New Product Launches In 2005
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps will support projected launches for ZyLET and Retisert following the end of a co-promotion agreement for MedPointe's Optivar. B&L expects action on the ZyLET NDA next year and on the Retisert application by year-end.
You may also be interested in...
Bausch & Lomb Will Conduct ZyLET Phase IV Study In 60 Young Children
Pediatric study is B&L’s only postmarketing commitment for the combination ophthalmic, FDA’s approval letter states. The company is expected to launch ZyLET in the first quarter of 2005.
Bausch & Lomb Will Conduct ZyLET Phase IV Study In 60 Young Children
Pediatric study is B&L’s only postmarketing commitment for the combination ophthalmic, FDA’s approval letter states. The company is expected to launch ZyLET in the first quarter of 2005.
Bausch & Lomb ZyLET Clears FDA
Loteprednol/tobramycin ophthalmic will be marketed by sales force that had been promoting the conjunctivitis agent Optivar.